Research
Hormonal
In women, a 21.8% decrease in bioavailable testosterone at year 1 mediated decreases in whole-body fat mass (-164; 95% CI, -326 to -29.3), whole-body lean mass (-115 g; 95% CI, -203.4 to -40), and trunk lean mass (-97.2 g; 95% CI, -156 to -45.5) at year 4.
Practitioners should consider the role of bioavailable testosterone in managing body composition in women with type 2 diabetes.
StrongSupportsmedium confidence
In women, a 21.8% decrease in bioavailable T (BioT) at Y1 mediated decreases in whole-body fat mass (-164; 95% CI, -326 to -29.3), whole-body lean mass (-115 g; 95% CI, -203.4 to -40), and trunk lean mass (-97.2 g; 95% CI, -156 to -45.5) at Y4.
Why this rating
Based on the analysis of a large participant group in a structured study.
Source
Role of Sex Hormones in Mediating Adiposity Changes From Weight Loss in People With Type 2 Diabetes: Look AHEAD Sex Hormone Study
Chigolum P. Oyeka et al. · The Journal of Clinical Endocrinology & Metabolism · 2025
DOI 10.1210/clinem/dgaf287
cohort · n=2334Cited 7×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- In men, a 14.4% ILI-associated increase in total testosterone at year 1 mediated increases in weight (189 g; 95% CI, 65-317) and waist circumference (0.135 cm; 95% CI, 0.19-0.248) at year 4.Strong
- The study revealed sex-specific mediating effects of sex hormones due to weight loss from intensive lifestyle intervention on body composition changes in people with type 2 diabetes.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →